At Uromigos Live 2024, a panel moderated by Brian Rini focused on the use of front-line therapy in papillary renal cancer and featured discussion on new and upcoming data in the field. The panel featured Tom Powles along with guests Laurence Albiges, MD, Institute Gustave-Roussy; David McDermott, MD, Beth Israel Deaconess Medical Center; and Hans Hammers, MD, UT Southwestern Medical Center.
In part 3 of the session, the panel discusses the latest developments in treatments for papillary kidney cancer, focusing on the evolving landscape of therapeutic options and the role of trials comparing new combinations against traditional treatments such as sunitinib. The panel shares insights on how emerging data may impact future standards of care, highlighting the challenges of balancing trial design with effective, patient-centered treatment. The conversation also touches on whether current trial designs, particularly around dual therapies and single-agent treatments, address the most pressing clinical questions.
Uromigos Live 2024 Front-Line Therapy in Papillary RCC Part 3: What Data is Forthcoming in Papillary RCC?
By Brian Rini, MD, FASCO, Thomas Powles, MBBS, MRCP, MD, Laurence Albiges, MD, PhD, David F. McDermott, MD, Hans Hammers, MD, PhD - Last Updated: October 30, 2024Related Posts
Drs. Beckermann and Braun discuss the latter's Nature publication on a personalized neoantigen vaccine for RCC.
Patients with mRCC on Medicare have better survival rates compared with patients on Medicaid or with no insurance.
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
The panel concludes with future directions in RCC, including HIF inhibitors and biomarker-guided adjuvant strategies.
The panel considers how managing real-world patients on novel therapies like belzutifan presents a multitude of challenges.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.